Endometriosis often takes years to diagnose. This ultrasound simulation innovation could help change that
Updated
March 17, 2026 1:01 AM
A group of women facing backwards. PHOTO: UNSPLASH
Endometriosis affects roughly one in ten women worldwide, yet diagnosing the condition often takes years. In many cases, patients experience symptoms for nearly a decade before receiving a confirmed diagnosis. One reason is that detecting endometriosis through ultrasound requires specialized training and clinicians do not always encounter enough real cases to build that expertise.
To address this gap, medical simulation company Surgical Science has introduced a new ultrasound training module designed specifically for identifying endometriosis. The system allows clinicians to practice scanning techniques in a virtual environment, helping them recognize signs of the disease without relying solely on real-patient cases.
A key feature of the simulator is training on the “sliding sign,” an ultrasound indicator used to detect deep endometriosis. Because the condition can appear differently from patient to patient, mastering this assessment in real clinical settings can be difficult. The simulator allows clinicians to repeat the process across multiple scenarios, improving their ability to identify the condition during routine examinations.
The module also incorporates the International Deep Endometriosis Analysis (IDEA) protocol, which provides a structured method for performing a complete pelvic ultrasound assessment. Additional training cases, region-based scenarios and certification options are included to support standardized learning.
Early training results suggest strong improvements in clinician confidence, including higher skill levels in transvaginal ultrasound and better recognition of deep endometriosis. By expanding access to structured ultrasound training, simulation tools like this could help reduce diagnostic delays and improve care for millions of women living with the condition.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.